Patrick Turner Posted September 4, 2019 Share Posted September 4, 2019 Hi all, there has been a conference in Basel in Switzerland discussing Pca. A summary of opinions is at https://www.urotoday.com/conference-highlights/apccc-2019.html I found the following info by a Dr Sartor at https://www.urotoday.com/conference-highlights/apccc-2019/114675-apccc-2019-radium-223-and-bone-health-agents-lessons-learned.html This makes sobering reading because Ra223 seems to cause more fractures away from sites with bone mets/fractures in bones but the "take home" message from Dr Sartor says that denosumab or zelodronic acid should be given before Ra223, and during its administration. Taking abiraterone while having Ra223 admin much increases bone fracture risk. I have wondered what effect Ra223 might have on areas of bone with arthritis and have not found an answer. I have not yet read about what the conference may have said about Lu177 or Ac225, but methinks where it is possible these two nuclides may be more effective and safer than Ra223 where a PsMa Ga68 scan shows that the mets have PsMa avidity. Meanwhile, I see no future benefit yet to have Ra223. I do seem to be getting a benefit following 4 x Lu177 shots after Nov 2018. Lu177 and general health has made it possible to cycle the 19km to and from home to Canberra Hospital to have a follow up chat with my oncologist. Regards to all, Patrick Turner. Link to comment Share on other sites More sharing options...
This topic is now archived and is closed to further replies.